Reuters logo
a month ago
BRIEF-Glenmark Pharmaceuticals licenses small molecule oncology compound from APC Therapeutics
June 21, 2017 / 3:21 AM / a month ago

BRIEF-Glenmark Pharmaceuticals licenses small molecule oncology compound from APC Therapeutics

1 Min Read

June 21 (Reuters) - Glenmark Pharmaceuticals Ltd

* Says entered into a licensing agreement with boston-based APC Therapeutics Inc

* Says licenses small molecule oncology compound from APC Therapeutics to expand immuno-oncology portfolio

* Compound has potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.

* Co will license product from apc therapeutics, manage clinical development including regulatory filings & commercialization worldwide

* APC Therapeutics will receive development milestones and sales royalty payments. Source text: (bit.ly/2rBip8Z) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below